Ensign Peak Advisors Inc Decreases Stock Position in RxSight, Inc. $RXST

Ensign Peak Advisors Inc cut its holdings in RxSight, Inc. (NASDAQ:RXST) by 22.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,100 shares of the company’s stock after selling 46,814 shares during the quarter. Ensign Peak Advisors Inc owned 0.39% of RxSight worth $2,068,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. GSA Capital Partners LLP lifted its holdings in shares of RxSight by 56.6% during the first quarter. GSA Capital Partners LLP now owns 38,456 shares of the company’s stock valued at $971,000 after purchasing an additional 13,892 shares in the last quarter. XTX Topco Ltd purchased a new position in RxSight in the 1st quarter worth about $540,000. Vanguard Group Inc. lifted its stake in RxSight by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 2,392,052 shares of the company’s stock valued at $60,399,000 after acquiring an additional 8,504 shares during the period. Nuveen LLC purchased a new stake in shares of RxSight during the 1st quarter valued at about $5,559,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of RxSight by 161.2% during the 1st quarter. Russell Investments Group Ltd. now owns 4,091 shares of the company’s stock valued at $103,000 after acquiring an additional 2,525 shares during the last quarter. Institutional investors own 78.78% of the company’s stock.

RxSight Price Performance

Shares of RxSight stock opened at $11.52 on Friday. RxSight, Inc. has a 1-year low of $6.32 and a 1-year high of $47.89. The company’s fifty day simple moving average is $9.06 and its 200-day simple moving average is $10.34. The stock has a market capitalization of $473.70 million, a PE ratio of -13.09 and a beta of 1.16.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.15. The firm had revenue of $30.34 million during the quarter, compared to analyst estimates of $25.63 million. RxSight had a negative return on equity of 12.82% and a negative net margin of 25.15%.RxSight’s revenue was down 31.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.16) EPS. RxSight has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that RxSight, Inc. will post -0.7 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on RXST shares. JPMorgan Chase & Co. boosted their price objective on shares of RxSight from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Thursday, November 6th. Zacks Research raised shares of RxSight from a “strong sell” rating to a “hold” rating in a research report on Monday, September 8th. Wells Fargo & Company increased their price target on RxSight from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Thursday, November 6th. Weiss Ratings restated a “sell (e+)” rating on shares of RxSight in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus set a $10.00 price objective on RxSight in a research report on Thursday, November 6th. One research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, RxSight has a consensus rating of “Reduce” and an average target price of $9.56.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.